Novartis Ag Stock Today
| NVSEF Stock | USD 98.25 6.75 6.43% |
Performance0 of 100
| Odds Of DistressLess than 10
|
Novartis is trading at 98.25 as of the 21st of November 2024. This is a 6.43 percent decrease since the beginning of the trading day. The stock's lowest day price was 98.25. Novartis has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Novartis AG are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. The company has 2.12 B outstanding shares. More on Novartis AG
Moving together with Novartis Pink Sheet
| 0.81 | LLY | Eli Lilly | PairCorr |
| 0.69 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.79 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.8 | RHHBY | Roche Holding | PairCorr |
| 0.81 | RHHVF | Roche Holding AG | PairCorr |
Moving against Novartis Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Novartis Pink Sheet Highlights
| Business Concentration | Drug Manufacturers—General, Healthcare (View all Sectors) |
Novartis AG [NVSEF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Mega-Cap' category with a current market capitalization of 183.29 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novartis's market, we take the total number of its shares issued and multiply it by Novartis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Novartis AG classifies itself under Healthcare sector and is part of Drug Manufacturers—General industry. The entity has 2.12 B outstanding shares.
Novartis AG has accumulated about 19.1 B in cash with 14.24 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.81.
Check Novartis Probability Of Bankruptcy
Ownership AllocationNovartis AG maintains a total of 2.12 Billion outstanding shares. 30% of Novartis outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Novartis Ownership Details
Novartis AG Risk Profiles
| Mean Deviation | 1.34 | |||
| Standard Deviation | 2.15 | |||
| Variance | 4.63 | |||
| Risk Adjusted Performance | (0.09) |
Novartis Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Novartis without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Risk-Return Analysis Now
Risk-Return AnalysisView associations between returns expected from investment and the risk you assume |
| All Next | Launch Module |
Novartis Corporate Management
| Richard Saynor | Chief Sandoz | Profile | |
| Steffen Lang | Global Head of Novartis Technical Operations, Member of the Executive Committee | Profile | |
| MarieFrance Tschudin | Pres Officer | Profile | |
| Paul Penepent | Head Accounting | Profile | |
| Samir MD | Global Relations | Profile | |
| Robert PharmD | Chief Officer | Profile | |
| Klaus Moosmayer | Chief Ethics Risk and Compliance Officer, Member of the Executive Committee | Profile |
Other Information on Investing in Novartis Pink Sheet
Novartis financial ratios help investors to determine whether Novartis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novartis with respect to the benefits of owning Novartis security.